Moreover, trastuzumab is being tested in combination with a programmed cell death 1 (PD-1) inhibitor, camrelizumab, in a phase II study (NCT05193292) in patients with HER2-positive CRC. Here, PDCD1 is linked to colorectal carcinoma.